Justin Daniel Salciccioli, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| European Union | 12 | 2022 | 157 | 1.810 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 13 | 2024 | 327 | 1.630 |
Why?
|
| Cardiopulmonary Resuscitation | 12 | 2024 | 985 | 1.520 |
Why?
|
| Heart Arrest | 13 | 2024 | 1494 | 1.310 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2024 | 565 | 1.280 |
Why?
|
| Thiamine | 3 | 2019 | 160 | 0.810 |
Why?
|
| Neuromuscular Blockade | 2 | 2013 | 146 | 0.810 |
Why?
|
| Asthma | 4 | 2024 | 6172 | 0.750 |
Why?
|
| Pellagra | 1 | 2019 | 7 | 0.690 |
Why?
|
| Niacin | 1 | 2019 | 118 | 0.630 |
Why?
|
| Vitamin B Complex | 2 | 2019 | 297 | 0.600 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2023 | 831 | 0.540 |
Why?
|
| Tongue | 1 | 2019 | 404 | 0.540 |
Why?
|
| Europe | 11 | 2024 | 3420 | 0.520 |
Why?
|
| Biological Products | 1 | 2024 | 906 | 0.500 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2023 | 930 | 0.480 |
Why?
|
| World Health Organization | 7 | 2024 | 1312 | 0.470 |
Why?
|
| Life Support Care | 1 | 2016 | 221 | 0.470 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 1274 | 0.460 |
Why?
|
| Databases, Factual | 10 | 2024 | 7980 | 0.450 |
Why?
|
| Glucocorticoids | 1 | 2023 | 2144 | 0.440 |
Why?
|
| School Health Services | 1 | 2017 | 380 | 0.430 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 747 | 0.430 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 621 | 0.420 |
Why?
|
| Diarrhea | 1 | 2019 | 1317 | 0.420 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 778 | 0.420 |
Why?
|
| Incidence | 22 | 2024 | 21272 | 0.400 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 856 | 0.390 |
Why?
|
| Hospital Mortality | 12 | 2022 | 5272 | 0.390 |
Why?
|
| Atrial Flutter | 2 | 2023 | 252 | 0.340 |
Why?
|
| Aortic Rupture | 2 | 2023 | 315 | 0.340 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 1275 | 0.330 |
Why?
|
| Lactic Acid | 4 | 2019 | 1133 | 0.330 |
Why?
|
| Quality-Adjusted Life Years | 7 | 2023 | 1722 | 0.320 |
Why?
|
| Hydroxyl Radical | 1 | 2008 | 83 | 0.320 |
Why?
|
| Peroxides | 1 | 2008 | 73 | 0.310 |
Why?
|
| Stilbenes | 1 | 2008 | 155 | 0.300 |
Why?
|
| Free Radical Scavengers | 1 | 2008 | 211 | 0.300 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 3216 | 0.290 |
Why?
|
| Lung Diseases | 1 | 2017 | 1910 | 0.280 |
Why?
|
| Prealbumin | 1 | 2008 | 222 | 0.280 |
Why?
|
| Female | 69 | 2024 | 390323 | 0.280 |
Why?
|
| Mortality | 11 | 2024 | 2886 | 0.280 |
Why?
|
| Male | 67 | 2024 | 358747 | 0.280 |
Why?
|
| Humans | 92 | 2024 | 758406 | 0.270 |
Why?
|
| Pneumonia | 1 | 2018 | 2129 | 0.270 |
Why?
|
| Education, Medical | 2 | 2017 | 1725 | 0.260 |
Why?
|
| Critical Illness | 2 | 2015 | 2703 | 0.250 |
Why?
|
| Myocardial Ischemia | 3 | 2022 | 2108 | 0.250 |
Why?
|
| Peripheral Arterial Disease | 3 | 2021 | 1246 | 0.240 |
Why?
|
| Hypothermia, Induced | 4 | 2014 | 756 | 0.240 |
Why?
|
| Heart Massage | 1 | 2024 | 31 | 0.240 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2017 | 2159 | 0.240 |
Why?
|
| Interleukin-5 | 1 | 2024 | 269 | 0.230 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2023 | 49 | 0.220 |
Why?
|
| Hungary | 1 | 2023 | 82 | 0.220 |
Why?
|
| Rheumatic Heart Disease | 1 | 2024 | 165 | 0.210 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2023 | 1426 | 0.210 |
Why?
|
| Rib Fractures | 1 | 2024 | 128 | 0.210 |
Why?
|
| Severity of Illness Index | 4 | 2012 | 15785 | 0.200 |
Why?
|
| Budesonide | 1 | 2023 | 158 | 0.200 |
Why?
|
| APACHE | 2 | 2012 | 267 | 0.200 |
Why?
|
| Neutrophils | 1 | 2015 | 3765 | 0.200 |
Why?
|
| Shock, Septic | 3 | 2014 | 761 | 0.200 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2023 | 1214 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 2 | 2021 | 1475 | 0.200 |
Why?
|
| Intensive Care Units | 6 | 2021 | 3732 | 0.190 |
Why?
|
| Thoracic Injuries | 1 | 2024 | 278 | 0.190 |
Why?
|
| Femoral Neck Fractures | 1 | 2022 | 141 | 0.190 |
Why?
|
| Stroke | 2 | 2022 | 9694 | 0.190 |
Why?
|
| Acidosis, Lactic | 2 | 2013 | 145 | 0.180 |
Why?
|
| Morbidity | 2 | 2023 | 1754 | 0.180 |
Why?
|
| Vasoconstrictor Agents | 3 | 2019 | 651 | 0.180 |
Why?
|
| Ubiquinone | 2 | 2012 | 182 | 0.180 |
Why?
|
| Administration, Inhalation | 1 | 2023 | 1153 | 0.170 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 433 | 0.170 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 1680 | 0.170 |
Why?
|
| Bronchodilator Agents | 1 | 2023 | 505 | 0.170 |
Why?
|
| Weather | 1 | 2020 | 226 | 0.170 |
Why?
|
| Body Temperature | 2 | 2014 | 777 | 0.170 |
Why?
|
| Steroids | 1 | 2024 | 926 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 7378 | 0.160 |
Why?
|
| Cytochromes c | 1 | 2019 | 173 | 0.160 |
Why?
|
| Endovascular Procedures | 2 | 2023 | 2139 | 0.160 |
Why?
|
| Leukocyte Count | 2 | 2015 | 1593 | 0.160 |
Why?
|
| Stockings, Compression | 1 | 2018 | 36 | 0.160 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 5103 | 0.160 |
Why?
|
| Respiratory Insufficiency | 2 | 2021 | 1230 | 0.160 |
Why?
|
| Epidemiologic Studies | 1 | 2022 | 670 | 0.150 |
Why?
|
| Endocarditis, Bacterial | 1 | 2022 | 442 | 0.150 |
Why?
|
| Endocarditis | 1 | 2022 | 349 | 0.150 |
Why?
|
| Brain Edema | 2 | 2014 | 603 | 0.150 |
Why?
|
| Piperacillin | 1 | 2017 | 37 | 0.150 |
Why?
|
| United States | 16 | 2024 | 72136 | 0.150 |
Why?
|
| Penicillanic Acid | 1 | 2017 | 41 | 0.140 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2023 | 559 | 0.140 |
Why?
|
| Gout | 1 | 2024 | 618 | 0.140 |
Why?
|
| Defibrillators | 1 | 2017 | 39 | 0.140 |
Why?
|
| Middle Aged | 35 | 2024 | 219568 | 0.140 |
Why?
|
| London | 1 | 2017 | 234 | 0.140 |
Why?
|
| Anaphylaxis | 1 | 2024 | 755 | 0.140 |
Why?
|
| Appendicitis | 1 | 2023 | 674 | 0.140 |
Why?
|
| Treatment Outcome | 16 | 2024 | 64378 | 0.140 |
Why?
|
| Disabled Persons | 2 | 2023 | 1224 | 0.130 |
Why?
|
| Graft Survival | 2 | 2023 | 3794 | 0.130 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2017 | 109 | 0.130 |
Why?
|
| Patient Preference | 1 | 2023 | 921 | 0.130 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2022 | 695 | 0.130 |
Why?
|
| Medical Audit | 1 | 2017 | 452 | 0.130 |
Why?
|
| Aged | 30 | 2024 | 168218 | 0.130 |
Why?
|
| Developed Countries | 3 | 2024 | 440 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 787 | 0.120 |
Why?
|
| Emergency Medical Services | 3 | 2016 | 1915 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 557 | 0.120 |
Why?
|
| Predictive Value of Tests | 8 | 2015 | 15225 | 0.120 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 943 | 0.120 |
Why?
|
| Hip Fractures | 1 | 2022 | 987 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2022 | 1160 | 0.110 |
Why?
|
| Sex Distribution | 3 | 2024 | 2284 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 1 | 2024 | 1564 | 0.110 |
Why?
|
| England | 3 | 2023 | 524 | 0.110 |
Why?
|
| Cost of Illness | 4 | 2024 | 1936 | 0.110 |
Why?
|
| Rewarming | 1 | 2013 | 64 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 6293 | 0.110 |
Why?
|
| Ventricular Function | 1 | 2014 | 406 | 0.110 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 58683 | 0.100 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2014 | 344 | 0.100 |
Why?
|
| Lactates | 1 | 2013 | 404 | 0.100 |
Why?
|
| Adult | 19 | 2024 | 219935 | 0.100 |
Why?
|
| Abdomen | 1 | 2018 | 1129 | 0.100 |
Why?
|
| Lower Extremity | 1 | 2020 | 1188 | 0.100 |
Why?
|
| Retrospective Studies | 21 | 2024 | 80168 | 0.100 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 5797 | 0.100 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2018 | 500 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2023 | 2325 | 0.100 |
Why?
|
| Austria | 2 | 2022 | 206 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2024 | 2040 | 0.100 |
Why?
|
| Czech Republic | 2 | 2022 | 73 | 0.100 |
Why?
|
| Sodium | 1 | 2017 | 1588 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2014 | 318 | 0.100 |
Why?
|
| Prevalence | 4 | 2024 | 15651 | 0.090 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 1647 | 0.090 |
Why?
|
| Myoclonus | 1 | 2011 | 107 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 1673 | 0.090 |
Why?
|
| Respiratory Rate | 1 | 2012 | 175 | 0.090 |
Why?
|
| Epinephrine | 1 | 2014 | 790 | 0.090 |
Why?
|
| Prospective Studies | 11 | 2019 | 54137 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 2650 | 0.090 |
Why?
|
| Sepsis | 1 | 2024 | 2587 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 931 | 0.090 |
Why?
|
| ROC Curve | 3 | 2012 | 3563 | 0.090 |
Why?
|
| Norway | 2 | 2022 | 496 | 0.090 |
Why?
|
| Cohort Studies | 8 | 2024 | 41256 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 13245 | 0.080 |
Why?
|
| Regression Analysis | 4 | 2021 | 6354 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2016 | 2359 | 0.080 |
Why?
|
| Logistic Models | 5 | 2017 | 13276 | 0.080 |
Why?
|
| Vertigo | 1 | 2011 | 202 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2014 | 970 | 0.080 |
Why?
|
| Sweden | 2 | 2023 | 1376 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 2016 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2023 | 3432 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 1501 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 2071 | 0.080 |
Why?
|
| Data Collection | 2 | 2022 | 3322 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2332 | 0.080 |
Why?
|
| Hydrogen Bonding | 1 | 2008 | 290 | 0.080 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 1263 | 0.080 |
Why?
|
| Career Choice | 1 | 2014 | 752 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 1845 | 0.080 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2011 | 253 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 812 | 0.080 |
Why?
|
| Schools | 1 | 2017 | 1482 | 0.070 |
Why?
|
| Positive-Pressure Respiration | 1 | 2012 | 636 | 0.070 |
Why?
|
| Crystallization | 1 | 2008 | 533 | 0.070 |
Why?
|
| Registries | 4 | 2021 | 8175 | 0.070 |
Why?
|
| Risk Factors | 7 | 2023 | 73809 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 9160 | 0.070 |
Why?
|
| Disease Progression | 1 | 2024 | 13468 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 1159 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2022 | 4217 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 7403 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 4023 | 0.070 |
Why?
|
| Recurrence | 1 | 2019 | 8426 | 0.070 |
Why?
|
| Bacteremia | 2 | 2012 | 980 | 0.070 |
Why?
|
| Age Distribution | 2 | 2024 | 2882 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 4312 | 0.070 |
Why?
|
| Lung | 1 | 2024 | 9985 | 0.070 |
Why?
|
| Telemedicine | 1 | 2023 | 3018 | 0.060 |
Why?
|
| Fever | 1 | 2013 | 1617 | 0.060 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2014 | 1066 | 0.060 |
Why?
|
| Time Factors | 5 | 2020 | 39872 | 0.060 |
Why?
|
| Patient Discharge | 4 | 2024 | 3433 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 1855 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1911 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 20500 | 0.060 |
Why?
|
| Liver | 1 | 2020 | 7502 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2010 | 820 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2008 | 1866 | 0.060 |
Why?
|
| Hospitals | 3 | 2023 | 3887 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3561 | 0.060 |
Why?
|
| Crystallography, X-Ray | 1 | 2008 | 1974 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5331 | 0.060 |
Why?
|
| General Surgery | 1 | 2014 | 1677 | 0.050 |
Why?
|
| Emergency Service, Hospital | 5 | 2014 | 7810 | 0.050 |
Why?
|
| Oxygen | 1 | 2014 | 4191 | 0.050 |
Why?
|
| Young Adult | 5 | 2023 | 58808 | 0.050 |
Why?
|
| Vitamins | 1 | 2011 | 1632 | 0.050 |
Why?
|
| Belgium | 1 | 2022 | 118 | 0.050 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2010 | 1031 | 0.050 |
Why?
|
| Ribs | 1 | 2024 | 252 | 0.050 |
Why?
|
| Luxembourg | 1 | 2021 | 1 | 0.050 |
Why?
|
| Bulgaria | 1 | 2021 | 17 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 12951 | 0.050 |
Why?
|
| Histocompatibility Testing | 1 | 2023 | 717 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 11336 | 0.050 |
Why?
|
| Health Status Disparities | 2 | 2024 | 1831 | 0.050 |
Why?
|
| Students, Medical | 1 | 2014 | 1927 | 0.050 |
Why?
|
| Ireland | 1 | 2021 | 171 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5691 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2011 | 2731 | 0.050 |
Why?
|
| Hospitalization | 1 | 2021 | 10652 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2011 | 2970 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2014 | 5460 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2010 | 2189 | 0.040 |
Why?
|
| Gross Domestic Product | 1 | 2020 | 78 | 0.040 |
Why?
|
| Graft Rejection | 2 | 2023 | 4426 | 0.040 |
Why?
|
| Survival Analysis | 4 | 2014 | 10112 | 0.040 |
Why?
|
| Hospitals, Urban | 2 | 2012 | 500 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4761 | 0.040 |
Why?
|
| Sunlight | 1 | 2020 | 337 | 0.040 |
Why?
|
| Germany | 1 | 2021 | 868 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2023 | 1368 | 0.040 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2018 | 24 | 0.040 |
Why?
|
| Adolescent | 4 | 2024 | 87892 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2011 | 3047 | 0.040 |
Why?
|
| Length of Stay | 1 | 2011 | 6439 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 3211 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2018 | 23884 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 12075 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2017 | 9650 | 0.040 |
Why?
|
| Cytokines | 1 | 2012 | 7338 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 7818 | 0.030 |
Why?
|
| Prognosis | 5 | 2019 | 29557 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 21017 | 0.030 |
Why?
|
| Australia | 1 | 2020 | 1276 | 0.030 |
Why?
|
| Northern Ireland | 1 | 2016 | 37 | 0.030 |
Why?
|
| Propensity Score | 1 | 2024 | 1907 | 0.030 |
Why?
|
| Wales | 1 | 2016 | 86 | 0.030 |
Why?
|
| Sex Factors | 2 | 2024 | 10504 | 0.030 |
Why?
|
| Scotland | 1 | 2016 | 143 | 0.030 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 3364 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 1076 | 0.030 |
Why?
|
| State Medicine | 1 | 2017 | 213 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 1870 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2023 | 2311 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2016 | 472 | 0.030 |
Why?
|
| Temperature | 1 | 2020 | 2219 | 0.030 |
Why?
|
| Ontario | 1 | 2014 | 397 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2024 | 1452 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 2528 | 0.030 |
Why?
|
| Age Factors | 3 | 2015 | 18358 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 1470 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 1378 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 1812 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 25956 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 10718 | 0.020 |
Why?
|
| Electric Countershock | 1 | 2014 | 533 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2023 | 2347 | 0.020 |
Why?
|
| Acute Disease | 2 | 2012 | 7225 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2014 | 460 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4839 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2014 | 8553 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2012 | 567 | 0.020 |
Why?
|
| Tidal Volume | 1 | 2012 | 487 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 14641 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2011 | 691 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 12096 | 0.020 |
Why?
|
| Calibration | 1 | 2011 | 814 | 0.020 |
Why?
|
| Child | 1 | 2017 | 79818 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39059 | 0.020 |
Why?
|
| Observation | 1 | 2010 | 311 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 10146 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15637 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 1632 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 22032 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8530 | 0.020 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2010 | 352 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2925 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 2640 | 0.020 |
Why?
|
| Mass Screening | 1 | 2021 | 5427 | 0.020 |
Why?
|
| Cross Infection | 1 | 2014 | 1432 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2248 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 4919 | 0.010 |
Why?
|
| Critical Care | 1 | 2017 | 2692 | 0.010 |
Why?
|
| Pandemics | 1 | 2024 | 8611 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2012 | 1296 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 10748 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 2374 | 0.010 |
Why?
|
| Quality of Life | 1 | 2023 | 13285 | 0.010 |
Why?
|
| Massachusetts | 1 | 2014 | 8823 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 12721 | 0.010 |
Why?
|
| Survivors | 1 | 2011 | 2370 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10495 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2012 | 4317 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3227 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 6852 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 36284 | 0.000 |
Why?
|